Zynex, Inc. (ZYXI)
ZYXI Stock Price Chart
Explore Zynex, Inc. interactive price chart. Choose custom timeframes to analyze ZYXI price movements and trends.
ZYXI Company Profile
Discover essential business fundamentals and corporate details for Zynex, Inc. (ZYXI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Distribution
IPO Date
25 Feb 2004
Employees
1.00K
Website
https://www.zynex.comCEO
Thomas Sandgaard
Description
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
ZYXI Financial Timeline
Browse a chronological timeline of Zynex, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.19, while revenue estimate is $22.71M.
Earnings released on 31 Jul 2025
EPS came in at -$0.32 falling short of the estimated -$0.13 by -146.15%, while revenue for the quarter reached $22.29M , missing expectations by -24.67%.
Earnings released on 28 Apr 2025
EPS came in at -$0.33 falling short of the estimated -$0.24 by -37.50%, while revenue for the quarter reached $26.58M , missing expectations by -19.46%.
Earnings released on 11 Mar 2025
EPS came in at -$0.02 falling short of the estimated $0.09 by -122.22%, while revenue for the quarter reached $45.97M , missing expectations by -14.00%.
Earnings released on 24 Oct 2024
EPS came in at $0.07 surpassing the estimated $0.06 by +16.67%, while revenue for the quarter reached $49.97M , missing expectations by -6.87%.
Earnings released on 25 Jul 2024
EPS came in at $0.04 falling short of the estimated $0.08 by -50.00%, while revenue for the quarter reached $49.88M , missing expectations by -4.24%.
Earnings released on 30 Apr 2024
EPS came in at $0.00 , while revenue for the quarter reached $46.53M , missing expectations by -2.43%.
Earnings released on 29 Feb 2024
EPS came in at $0.04 falling short of the estimated $0.17 by -76.47%, while revenue for the quarter reached $47.28M , missing expectations by -13.29%.
Earnings released on 26 Oct 2023
EPS came in at $0.10 surpassing the estimated $0.09 by +11.11%, while revenue for the quarter reached $49.92M , missing expectations by -8.46%.
Earnings released on 27 Jul 2023
EPS came in at $0.09 surpassing the estimated $0.05 by +80.00%, while revenue for the quarter reached $44.95M , beating expectations by +0.68%.
Earnings released on 27 Apr 2023
EPS came in at $0.04 surpassing the estimated $0.01 by +200.08%, while revenue for the quarter reached $42.17M , beating expectations by +6.46%.
Earnings released on 13 Mar 2023
EPS came in at $0.20 surpassing the estimated $0.19 by +5.26%, while revenue for the quarter reached $48.81M , missing expectations by -1.82%.
Earnings released on 27 Oct 2022
EPS came in at $0.13 surpassing the estimated $0.12 by +8.33%, while revenue for the quarter reached $41.52M , beating expectations by +0.34%.
Earnings released on 28 Jul 2022
EPS came in at $0.08 surpassing the estimated $0.07 by +14.29%, while revenue for the quarter reached $36.76M , beating expectations by +1.28%.
Earnings released on 28 Apr 2022
EPS came in at $0.03 falling short of the estimated $0.05 by -40.00%, while revenue for the quarter reached $31.08M , beating expectations by +0.57%.
Earnings released on 24 Feb 2022
EPS came in at $0.23 surpassing the estimated $0.20 by +15.00%, while revenue for the quarter reached $40.37M , missing expectations by -2.32%.
Stock split effective on 5 Jan 2022
Shares were split 11 : 10 , changing the number of shares outstanding and the price per share accordingly.
Dividend declared on 10 Nov 2021
A dividend of $0.10 per share was announced, adjusted to $0.09. The dividend was paid on 21 Jan 2022.
Earnings released on 2 Nov 2021
EPS came in at $0.15 surpassing the estimated $0.11 by +36.36%, while revenue for the quarter reached $34.79M , missing expectations by -2.09%.
Earnings released on 29 Jul 2021
EPS came in at $0.07 surpassing the estimated $0.06 by +16.67%, while revenue for the quarter reached $31.02M , missing expectations by -0.76%.
Earnings released on 29 Apr 2021
EPS came in at -$0.02 falling short of the estimated -$0.02 by -23.08%, while revenue for the quarter reached $24.13M , missing expectations by -25.00%.
Earnings released on 25 Feb 2021
EPS came in at $0.05 falling short of the estimated $0.06 by -16.67%, while revenue for the quarter reached $25.61M , missing expectations by -14.29%.
Earnings released on 27 Oct 2020
EPS came in at $0.04 falling short of the estimated $0.05 by -20.00%, while revenue for the quarter reached $20.03M , missing expectations by -20.00%.
ZYXI Stock Performance
Access detailed ZYXI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.